TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus

Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents a small aortic annulus (SAA), especially women. Treating this group of patients remains challenging, seeing as they have a high incidence of suboptimal hemodynamic results. 

TCT 2023 | Ensayo VIVA: TAVI vs. Cirugía en Pacientes con Estenosis Aórtica Severa y Anillo Aórtico Pequeño

Despite the development of TAVR (transcatheter aortic valve replacement), the current guidelines do not take into account annulus size, hemodynamic outcomes of prosthetic valves or gender. There are data from observational and sub studies suggesting the superiority of TAVR vs surgical aortic valve replacement (SAVR) in the treatment of patients with SAA.  

The aim of this multicenter randomized study was to compare hemodynamic and clinical outcomes of TAVR vs SAVR in the treatment of AS with SAA.

Primary end point was defined as improved hemodynamic results, including severe patient-prosthesis mismatch (PPM) and/or moderate-severe aortic regurgitation (AR) at 60 days. Secondary end point included mean transvalvular gradient at 60 days, as well as clinical variables such as mortality, stroke, major bleeding, de novo atrial fibrillation, definite pacemaker implantation and rehospitalization for cardiac causes at 30 days. 

Read also: TCT 2023 | TRILUMINATE Trial: Health Status after TriClip.

A total 156 patients were randomized, 79 were treated with TAVR and 75 with SAVR. Mean age was 75, and patients were mostly women. Mean STS score was 2.5. Mean annulus diameter was 21.1 mm. Most TAVR patients received self-expanding valves (59.2%) followed by balloon expandable valves (40.8%), and mean prosthetis size was 23 mm. 

There were no differences between the groups as regards severe PPM or moderate-severe AR (severe PPM: TAVR: 5.6%, SAVR: 10.3%, p=0.30) and AR moderate-severe (none in both groups). Neither were there differences in mortality or stroke at 30 days. After mean 2-year followup, there were no differences in mortality (p=0.89), stroke (p=0.95) or cardiac hospitalization (p=0.80).

Conclusion

In patients with AS and SAA, no significant differences were found between TAVR and SAVR as regards hemodynamic valve outcomes at 2 year followup. These findings suggest that both therapeutic strategies are valid options to treat patients with AS and SAA, and that treatment should be decided on a case by case basis according to baseline characteristics, additional anatomical risk factors and patient preference. However, we should interpret outcomes with precaution seeing the limited size of this study population. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial.

Reference: Josep Rodés-Cabau, MD, PhD et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...